《新股消息》傳諾輝健康最快明年初來港集資3億美元
據《路透》旗下IFR引述消息人士指,內地癌症早期篩查產品製造商諾輝健康科技最快明年初在港上市,集資3億美元。
諾輝健康已於昨日遞交主板上市申請,高盛及瑞銀為聯席保薦人。初步招股資料顯示,旗下兩款結直腸癌早期篩查產品已獲得國家藥監局批准,胃癌及宮頸癌等其他候選產品則處於開發及註冊試驗階段。截至今年6月底止中期,諾輝健康虧損錄5.52億元人民幣,較2019年同期的1,488.3萬元人民幣有所增加,主要受優先股的公允價值變動所影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.